AstraZeneca Vaccine: Single Dose Efficacy and Optimal Interval Timing
A single dose of the AstraZeneca vaccine shows 76.0% efficacy for up to 90 days, with delayed booster dose administration at 12 weeks associated with substantially higher efficacy (81.3%), informing vaccination strategies and dose scheduling recommendations.
November 2021
First Dose Efficacy of Oxford Vaccine: Evidence from Real-World Data
Real-world evidence confirms the high efficacy of a single dose of the Oxford vaccine within 90 days of vaccination, underscoring the importance of timely vaccination strategies in controlling the spread of COVID-19 and preventing severe disease outcomes.
November 2021
Delaying Second Dose of COVID-19 Vaccines: Considerations and Concerns
Concerns persist regarding the effectiveness of delaying the second dose of COVID-19 vaccines, especially in older adults, underscoring the need for evidence-based vaccination strategies and continued monitoring of vaccine efficacy and safety profiles.
November 2021
AstraZeneca Vaccine Clinical Trial Results in the US: Efficacy and Safety Profile
AstraZeneca vaccine demonstrates 100% efficacy in preventing severe cases and 79% efficacy in preventing COVID-19 symptoms, supporting its role in vaccination campaigns and contributing to global efforts to control the spread of the virus.
October 2021
Vaccination and Invasive Cervical Cancer Risk Reduction: HPV Vaccine Benefits
HPV vaccination aims to prevent invasive cervical cancer by targeting oncogenic HPV types, highlighting its role in primary prevention efforts and reducing cancer burden through widespread vaccine coverage and immunization programs.
June 2021
Protective Immunity against SARS-CoV-2: Immunological Considerations and Challenges
Uncertainty regarding immunological correlates of protection against SARS-CoV-2 poses challenges in defining protective immunity thresholds and informing vaccination strategies, emphasizing the need for continued research and surveillance to guide public health policies and interventions.
December 2020
WHO to Conduct Clinical Trials for Avian Flu Vaccine in Humans
The World Health Organization (WHO) announces plans to commence clinical trials for an avian flu vaccine, prepared in collaboration with the WHO Global Influenza Network, aimed at addressing the ongoing threat of avian flu outbreaks and protecting public health globally.
August 2004
